All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View AML content recommended for you
Just one test to diagnose AML? Experts from King’s College London comment on NGS
The diagnosis of hematologic malignancies is not a straightforward procedure. There are many specialisms required to undertake morphological analysis, flow cytometry, cytogenetic, and molecular genetic analyses.
In an article published in Blood, Richard Dillon and the late David Grimwade from King’s College London provide an expert commentary on the work by McKerrell et al. relating to a novel Next-Generation Sequencing (NGS) platform. McKerrell and his colleagues developed and validated Karyogene, a comprehensive one-stop diagnostic platform for the genomic analysis of myeloid malignancies. According to Dillon and Grimwade, this novel platform can identify point mutations, common fusion genes and copy-number alterations in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) from a single genomic DNA sample.
McKerrell et al. validated this method against 62 AML, 50 MDS and 40 blood DNA samples from individuals without evidence of clonal blood disorders.
Their key findings demonstrated detection of sequence changes in 49 genes, including the prognostically important but difficult to identify FLT3-ITD mutation. In addition, there was the robust detection of all occurrences of one of the four common AML-associated translocations, namely t(15;17)/PML-RARA (9/9), inv(16)/CBFB-MYH11 (8/8), t(8;21)/RUNX1-RUNXT1 (4/4), and MLL fusions (8/8). The study was published in Blood in 2016.
Grimwade and Dillon conclude that, while this novel platform is very promising for the future of diagnosis of hematological malignancies such as AML, there are still some caveats regarding the use of the NSG based diagnostic tool. They state that in order to fully maximize diagnostic potential of this platform, it is necessary for RNA (as well as DNA) to be routinely extracted at diagnosis in order to provide baseline samples that allow molecular monitoring of Minimal Residual Disease.
Please find the full commentary by Grimwade and Dillon in Blood here.
References